161 related articles for article (PubMed ID: 36816798)
1. Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms.
Dambrauskienė R; Gerbutavičius R; Rudžianskienė M; Paukštaitienė R; Vitkauskienė A; Skrodenienė E; Remeikienė D; Zaborienė I; Juozaitytė E
Open Life Sci; 2023; 18(1):20220545. PubMed ID: 36816798
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non
Dambrauskienė R; Gerbutavičius R; Ugenskienė R; Jankauskaitė R; Savukaitytė A; Šimoliūnienė R; Rudžianskienė M; Gerbutavičienė R; Juozaitytė E
Balkan J Med Genet; 2017 Jun; 20(1):35-42. PubMed ID: 28924539
[TBL] [Abstract][Full Text] [Related]
3. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus.
Jiménez S; Tàssies D; Espinosa G; García-Criado A; Plaza J; Monteagudo J; Cervera R; Reverter JC
Ann Rheum Dis; 2008 Jun; 67(6):835-40. PubMed ID: 17728329
[TBL] [Abstract][Full Text] [Related]
4. 807C/T polymorphism of platelet glycoprotein Ia gene is associated with cerebral hemorrhage in a Chinese population.
Zeng Y; Zhang L; Hu Z; Yang Q; Ma M; Liu B; Xia J; Xu H; Liu Y; Du X
Int J Neurosci; 2016 Aug; 126(8):729-33. PubMed ID: 26134877
[TBL] [Abstract][Full Text] [Related]
5. LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.
Ochoa E; Iriondo M; Manzano C; Fullaondo A; Villar I; Ruiz-Irastorza G; Zubiaga AM; Estonba A
PLoS One; 2016; 11(1):e0146990. PubMed ID: 26820623
[TBL] [Abstract][Full Text] [Related]
6. Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India.
Ahluwalia J; Singh S; Naseem S; Suri D; Rawat A; Gupta A; Masih J; Bose S
Rheumatol Int; 2014 May; 34(5):669-73. PubMed ID: 23563494
[TBL] [Abstract][Full Text] [Related]
7. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies.
Jy W; Tiede M; Bidot CJ; Horstman LL; Jimenez JJ; Chirinos J; Ahn YS
Thromb Res; 2007; 121(3):319-25. PubMed ID: 17582471
[TBL] [Abstract][Full Text] [Related]
8. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
Kissova J; Bulikova A; Ovesna P; Bourkova L; Penka M
Int J Hematol; 2014 Nov; 100(5):429-36. PubMed ID: 25227185
[TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia.
Bidot CJ; Jy W; Horstman LL; Ahn ER; Bidot L; Fontana V; Ahn YS
Hematology; 2005 Dec; 10(6):451-6. PubMed ID: 16321809
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study.
Shah R; Mohammed YN; Koehler TJ; Kaur J; Toufeili M; Pulipati P; Alqaysi A; Khan A; Khalid M; Lee Y; Dhillon P; Dan AT; Kumar N; Bowen M; Sule AA; Krishnamoorthy G
PLoS One; 2022; 17(7):e0269466. PubMed ID: 35834511
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of the antiphospholipid syndrome.
Chaturvedi S; McCrae KR
Blood Rev; 2017 Nov; 31(6):406-417. PubMed ID: 28784423
[TBL] [Abstract][Full Text] [Related]
12. Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications.
Willemze R; Bradford RL; Mooberry MJ; Roubey RA; Key NS
Thromb Res; 2014 Feb; 133(2):187-9. PubMed ID: 24332063
[TBL] [Abstract][Full Text] [Related]
13. Mean platelet volume and risk of thrombotic and bleeding complications in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
Krashin E; Cohen O; Pereg D; Lishner M; Leader A
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):288-293. PubMed ID: 29474204
[TBL] [Abstract][Full Text] [Related]
14. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Antiphospholipid Antibodies in Patients With Immune Thrombocytopenia and Correlation With Treatment With Steroids in North Indian Population.
Dayama A; Dass J; Mahapatra M; Saxena R
Clin Appl Thromb Hemost; 2017 Sep; 23(6):657-662. PubMed ID: 27067744
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
Feng Y; Zhang Y; Shi J
Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
[TBL] [Abstract][Full Text] [Related]
17. Receptors involved in cell activation by antiphospholipid antibodies.
Brandt KJ; Kruithof EK; de Moerloose P
Thromb Res; 2013 Oct; 132(4):408-13. PubMed ID: 24054056
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome].
Melikyan AL; Subortseva IN; Koloshejnova EA; Gilyazitdinova EA; Shashkina KS; Gorgidze LA; Tratsevskaya ZV; Margolin OV
Ter Arkh; 2019 Jul; 91(7):93-99. PubMed ID: 32598741
[TBL] [Abstract][Full Text] [Related]
19. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
20. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS).
Bidot CJ; Jy W; Horstman LL; Ahn ER; Yaniz M; Ahn YS
Am J Hematol; 2006 Jun; 81(6):391-6. PubMed ID: 16680753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
